COCP logo

COCRYSTAL PHARMA INC

COCPNASDAQ
πŸ† #4569 by market capUS Equity
$1.04β€”
Last available close Β· quote unavailable
πŸ””
Track COCP
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–² 2.5%
14dβ–² 4.0%
30dβ–² 9.5%
ytdβ–² 7.2%
1yβ–² 10.6%
🏦Market Cap
$18M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
41.2%
Healthy
πŸ’΅FCF Margin
603.0%
Strong
βš–οΈP/S Ratio
55.5x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
β€”
52-Week Range
$0.76 – $2.03
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
19.3M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$105,000
P/E Ratio
β€”
P/S Ratio
55.5x
EPS (TTM)
$-0.76
Dividend Yield
β€”
Dilution (1yr)
+11.0%
COCP logo

COCRYSTAL PHARMA INC

COCP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$9Mβ–Ό βˆ’49.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$8Mβ–Ό βˆ’50.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.3Mβ–² +11.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6Mβ–Ό βˆ’$3M YoY
StockOtter Β· stockotter.space

About COCRYSTAL PHARMA INC

Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.